Key result
Preoperative systemic corticosteroids in COPD linked to ~10% wound complication rate without reducing PPCs.
Why the study?
COPD patients face increased risk of postoperative pulmonary complications, but the risks and benefits of preoperative steroids in this population require evaluation.
Does preoperative systemic corticosteroid therapy reduce postoperative pulmonary complications or increase wound complications in COPD patients undergoing surgery?
Cohort (n=92)
No
Does preoperative systemic corticosteroid therapy reduce postoperative pulmonary complications or increase wound complications in COPD patients undergoing surgery?
Absolute Event Rate: 17.9% vs 13.2%
p-value: p=0.53
Preoperative systemic corticosteroids in stable COPD patients undergoing surgery are associated with increased wound complications without reducing postoperative pulmonary complications.
May increase wound complications without reducing PPCs; leaves open preoperative steroid role in COPD surgery pending RCTs.
BACKGROUND: Chronic obstructive pulmonary disease (COPD) patients are at an increased risk of postoperative pulmonary complications (PPCs). The purpose of this study is to evaluate the risks and benefits associated with preoperative steroids in COPD patients. METHODS: The National Surgical Quality Improved Program database was used to identify 92 COPD patients who underwent surgery at the American University of Beirut Medical Center between 2009 and 2013. COPD was diagnosed based on postbronchodilator forced expiratory volume in 1 s to forced vital capacity ratio <0.7 and a history of smoking. The exposure of interest was preoperative systemic corticosteroid therapy. The primary outcomes were PPCs and wound complications. Cardiac and urinary complications along with unplanned readmission or reoperation and death were also evaluated. RESULTS: Overall 42.4% of patients received preoperative systemic corticosteroids. Postoperative wound complications were significantly more frequent in COPD patients who received preoperative systemic corticosteroids compared to patients who did not (10.3% vs. none, respectively, P = 0.03). However, PPCs were not significantly different between patients who received preoperative systemic corticosteroids and patients who did not (17.9% vs. 13.2%, respectively, P = 0.53). There were no significant differences in the secondary outcomes. CONCLUSIONS: This study suggests that preoperative administration of systemic corticosteroids in stable COPD patients is associated with an increased risk of postoperative wound complications but may not reduce PPCs.
No takes yet. Share an insight, caveat, or question.
Chami et al. (2019) conducted a cohort in Chronic obstructive pulmonary disease (COPD) (n=92). Preoperative systemic corticosteroid therapy vs. No preoperative systemic corticosteroids was evaluated on Postoperative pulmonary complications (PPCs) (p=0.53). Preoperative systemic corticosteroids in COPD patients increased postoperative wound complications (10.3% vs 0%; P=0.03) without significantly reducing PPCs (17.9% vs 13.2%; P=0.53).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: